It is time to end our love affair with short-acting $\beta_2$-agonists in asthma

Michael G. Crooks$^{1,2}$ and Shoaib Faruqi$^2$

$^1$Respiratory Research Group, Hull York Medical School, University of Hull, Kingston upon Hull, UK. $^2$Hull University Teaching Hospitals NHS Trust, Kingston upon Hull, UK.

Corresponding author: Michael G. Crooks (michael.crooks@nhs.net)

Shareable abstract (@ERSpublications)

In this issue of *ERJ Open Research*, NOORDUYN et al. add data to the growing literature showing that SABA overuse in asthma is both common and associated with severe exacerbations. It is time to take note and act to tackle this global issue. https://bit.ly/3BfwhF5

Cite this article as: Crooks MG, Faruqi S. It is time to end our love affair with short-acting $\beta_2$-agonists in asthma. *ERJ Open Res* 2022; 8: 00353-2022 [DOI: 10.1183/23120541.00353-2022].

Asthma is the most prevalent chronic respiratory disease worldwide and despite advances in our understanding of asthma and its treatment, it continues to be associated with significant, and largely preventable, morbidity and mortality [1, 2].

The world’s love affair with short-acting $\beta_2$-agonists (SABA) began in the 1960s when Sir David Jack discovered salbutamol, the first selective $\beta_2$-adrenoceptor agonist for the treatment of bronchospasm, heralding a paradigm change in asthma management [3, 4]. Salbutamol was quickly marketed and is the most widely prescribed asthma treatment to this day. Around the same time, the inhaled corticosteroid (ICS) beclomethasone dipropionate was also developed [5] but it took longer to prove efficacy and consequently was almost discarded as “useless” [6]. Now, the inflammatory nature of asthma is well understood and we recognise that the advent of ICS was associated with significant reductions in asthma mortality [7]. But while biologic agents have transformed the management of severe asthma; overall, improvements in asthma outcomes have stalled in recent years and our relationship with SABA may be to blame.

In this issue of *ERJ Open Research*, NOORDUYN et al. [8] report the findings of the latest in the series of the SABA in Asthma (SABINA) studies [9–15], SABINA Canada (table 1). In this study, the authors use administrative claims data from two Canadian cohorts with a combined population of 115 478 patients to assess the prevalence of SABA overuse and its association with severe asthma exacerbations. For the purpose of their analysis, a severe exacerbation is defined as dispensation of a course of oral corticosteroids of $\leq 10$ days duration or hospitalisation or emergency department attendance with asthma as the primary complaint. Consistent with other studies in the SABINA programme [12, 13, 16], NOORDUYN et al. [8] identified a high prevalence of SABA overuse in both Canadian cohorts (28% in the Alberta cohort and 39% in the Nova Scotia cohort), and an association between SABA overuse and severe exacerbations, with the highest exacerbation rate observed in those with the highest SABA use.

These findings should not come as a surprise. While SABA provide effective rapid relief of bronchoconstriction and its associated symptoms, a trait that leads patients to develop a strong emotional attachment to them [17], SABA have no inherent anti-inflammatory properties [18] and therefore fail to address the core underlying problem in asthma. A wealth of data has accrued over recent years demonstrating that SABA overuse in asthma is associated with adverse outcomes such as exacerbations [9, 10, 12, 14], hospital admissions [19] and death [1, 14]. However, there is a lack of understanding and complacency about the implications of SABA overuse among patients and clinicians, contributing to acceptance of poor asthma control [17, 20]. The UK Royal College of Physicians National Review of Asthma Deaths (2014) identified excessive prescribing of reliever medication and under prescribing of...
preventer medication as a factor in asthma deaths [1]. Despite this, community prescribing data from England (2017) reveal SABA to be the most commonly prescribed class of inhaled treatment, with 21.9 million SABA inhalers prescribed per year. This compares with 6.7 million ICS and 14.1 million ICS/LABA combination inhalers [21].

The concept of combining ICS with fast-acting bronchodilators in order to improve asthma control is not new [22]. But it is only recently that recognition of the risk associated with treating asthma with SABA alone and the association between SABA overuse and exacerbations has led the Global Initiative for Asthma (GINA) [23] to change their guidance. In mild asthma (steps 1–2), GINA cite combined ICS/formoterol as the preferred reliever, escalating to ICS/formoterol maintenance and reliever therapy (MART) for those requiring regular preventer therapy (step 3).

In mild asthma, combined budesonide/formoterol used as required is associated with reduced risk of exacerbation, hospitalisation and systemic corticosteroid exposure when compared with use of a fast-acting bronchodilator (SABA or formoterol) alone [24]. Likewise, use of either budesonide or beclomethasone in combination with formoterol as MART, has also consistently been shown to improve asthma control and reduce exacerbation risk and systemic corticosteroid exposure compared with fixed-dose ICS/LABA combination preventer therapy with SABA reliever [25, 26].

When faced with such data about the negative association between SABA overuse and patient outcomes, and the existence of an alternative approach to asthma management that could render SABA obsolete for many; we must ask ourselves why SABA remains the most prescribed asthma treatment? Indeed, this question becomes even more pertinent when we consider the global challenge faced by climate change. Because in addition to the negative implications that SABA overuse has for asthma patients, there is increasing recognition that SABA is a major contributor to the carbon footprint of inhaled therapies. This is particularly true in countries like the UK, where 94% of the 21.9 million SABA inhalers prescribed each year are greenhouse gas-containing pressurised metered-dose inhalers [21], the consequence being that SABA account for 70% of the UK’s inhaler-related carbon footprint, totalling 863 kt carbon dioxide equivalent annually [27]. Such recognition is clearly cause for concern as climate change represents a significant risk to global health and mitigating this risk is a World Health Organization priority [28].

| First author [ref.] | Country | Population size (n) | Prevalence of SABA overuse (% patients) | Association between SABA overuse and asthma exacerbations |
|---------------------|---------|---------------------|----------------------------------------|--------------------------------------------------------|
| NOORDUYN [8]        | Canada  | 115 478             |                                        | SABA overuse was associated with an increased mean±SD exacerbation rate |
| Alberta             | 107 444 | 28.0                | 0.31±0.86 versus 0.17±0.62             |
| Nova Scotia         | 8034    | 39.4                | 0.46±1.11 versus 0.3±1.36              |
| NHARU [14]          | Sweden  | 365 324             |                                        | Positive association observed between number of SABA cannisters issued and exacerbation risk (hazard ratio (95% CI)) |
| ≤2 cannisters: 1.00 |                     |                     |                                        |
| 3–5 cannisters: 1.26 (1.24–1.28) |                     |                     |                                        |
| 6–10 cannisters: 1.44 (1.41–1.46) |                     |                     |                                        |
| ≥11 cannisters: 1.77 (1.72–1.83)  |                     |                     |                                        |
| BLOOM [12]          | UK      | 574 913             | 38                                     | SABA overuse was associated with increased risk of exacerbation across asthma severities (adjusted hazard ratio (95% CI)) |
| BTS steps 1 and 2: 1.2 (1.16–1.24) |                     |                     |                                        |
| BTS steps 3–5: 1.24 (1.20–1.28)  |                     |                     |                                        |
| BATeman [10]        | Multicountry | 8351             | 38                                     | SABA overuse was associated with increased exacerbation incidence (adjusted incidence rate ratio (95% CI)) |
| 3–5 cannisters: 1.40 (1.24–1.58) |                     |                     |                                        |
| 6–9 cannisters: 1.52 (1.33–1.74)  |                     |                     |                                        |
| 10–12 cannisters: 1.78 (1.57–2.02) |                     |                     |                                        |
| ≥13 cannisters: 1.92 (1.61–2.29)  |                     |                     |                                        |

BTS: British Thoracic Society.

The concept of combining ICS with fast-acting bronchodilators in order to improve asthma control is not new [22]. But it is only recently that recognition of the risk associated with treating asthma with SABA alone and the association between SABA overuse and exacerbations has led the Global Initiative for Asthma (GINA) [23] to change their guidance. In mild asthma (steps 1–2), GINA cite combined ICS/formoterol as the preferred reliever, escalating to ICS/formoterol maintenance and reliever therapy (MART) for those requiring regular preventer therapy (step 3).

In mild asthma, combined budesonide/formoterol used as required is associated with reduced risk of exacerbation, hospitalisation and systemic corticosteroid exposure when compared with use of a fast-acting bronchodilator (SABA or formoterol) alone [24]. Likewise, use of either budesonide or beclomethasone in combination with formoterol as MART, has also consistently been shown to improve asthma control and reduce exacerbation risk and systemic corticosteroid exposure compared with fixed-dose ICS/LABA combination preventer therapy with SABA reliever [25, 26].

When faced with such data about the negative association between SABA overuse and patient outcomes, and the existence of an alternative approach to asthma management that could render SABA obsolete for many; we must ask ourselves why SABA remains the most prescribed asthma treatment? Indeed, this question becomes even more pertinent when we consider the global challenge faced by climate change. Because in addition to the negative implications that SABA overuse has for asthma patients, there is increasing recognition that SABA is a major contributor to the carbon footprint of inhaled therapies. This is particularly true in countries like the UK, where 94% of the 21.9 million SABA inhalers prescribed each year are greenhouse gas-containing pressurised metered-dose inhalers [21], the consequence being that SABA account for 70% of the UK’s inhaler-related carbon footprint, totalling 863 kt carbon dioxide equivalent annually [27]. Such recognition is clearly cause for concern as climate change represents a significant risk to global health and mitigating this risk is a World Health Organization priority [28].
But, with recognition comes opportunity, providing another reason why tackling SABA overuse should be a priority for policymakers as well as clinicians and their patients.

Stopping SABA overuse is not easy, and the reasons why clinicians continue to prescribe and patients continue to overuse SABA are multiple and complex. Achieving asthma control, and thereby rendering patients free of symptoms and not reliant on reliever inhalers, would solve this problem. But in practice, important elements of asthma care such as adherence review, provision of written asthma action plans and structured symptom assessment are often not performed [29]. Patients’ lack of understanding about asthma, failure to recognise the importance of ICS and normalisation of their symptoms also make this more difficult to achieve [17, 29]. While most physicians recognise that a major barrier to medication adherence is patients only taking their treatment “when needed”, awareness of MART as a therapeutic option is variable and some primary care clinicians have never prescribed it [29].

There are therefore many barriers that need to be overcome if we are to tackle SABA overuse. However, through understanding the barriers, interventions can be developed to overcome them. We can start by equipping patients and clinicians with the required knowledge and resources to identify and address SABA overuse, ensuring patients can access high-quality asthma care through structured reviews and enabling access to ICS/formoterol reliever or MART for appropriate patients [30, 31].

Data can be a powerful tool, both in terms of identifying the problem, as Noorduyn et al. [8] have in their study, but also to provide feedback to patients, clinicians, funders and policy makers when practice change takes place. The time has come to act on the data and resurrect the improvements in global asthma outcomes that began with the discovery of ICS.

Provenance: Commissioned article, peer reviewed.

Conflict of interest: M.G. Crooks has received speaker fees and/or nonfinancial support from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis and Pfizer; has sat on advisory boards for AstraZeneca and Chiesi; and has received grants from AstraZeneca, Boehringer Ingelheim, Chiesi and Pfizer. S. Faruqi has received speaker fees from AstraZeneca, GSK, Chiesi and Novartis.

References

1. Levy ML. The national review of asthma deaths: what did we learn and what needs to change? Breathe 2015; 11: 14–24.
2. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med 2017; 5: 691–706.
3. Cullum VA, Farmer JB, Jack D, et al. Salbutamol: a new, selective beta-adrenoceptive receptor stimulant. Br J Pharmacol 1969; 35: 141–151.
4. Page C, Humphrey P. Sir David Jack: an extraordinary drug discoverer and developer. Br J Clin Pharmacol 2013; 75: 1213–1218.
5. Brown HM, Storey G, George WH. Beclomethasone dipropionate: a new steroid aerosol for the treatment of allergic asthma. Br Med J 1972; 1: 585–590.
6. Brown HM. How the first effective inhaled corticosteroid was almost discarded as useless. Ann Allergy Asthma Immunol 2007; 98: 602–603.
7. Ebmeyer S, Thayabaran D, Braithwaite I, et al. Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993–2012). Lancet 2017; 390: 935–945.
8. Noorduyn SG, Qian C, Johnston KM, et al. SABA use as an indicator for asthma exacerbation risk: an observational cohort study (SABINA Canada). ERJ Open Res 2022; 8: 00140-2022.
9. Quint JK, Arnetorp S, Kocks JWH, et al. Short-acting beta-2-agonist exposure and severe asthma exacerbations: SABINA findings from Europe and North America. J Allergy Clin Immunol Pract 2022; 10: 2297–2309.e10.
10. Bateman ED, Price DB, Wang HC, et al. Short-acting β2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study. Eur Respir J 2022; 59: 2101402.
11. Janson C, Menzies-Gow A, Nan C, et al. SABINA: an overview of short-acting β2-agonist use in asthma in European countries. Adv Ther 2020; 37: 1124–1135.
12. Bloom CI, Cabrera C, Arnetorp S, et al. Asthma-related health outcomes associated with short-acting β2-agonist inhaler use: an observational UK study as part of the SABINA global program. Adv Ther 2020; 37: 4190–4208.

https://doi.org/10.1183/23120541.00353-2022
13 Montero-Arias F, Garcia JCH, Gallego MP, et al. Over-prescription of short-acting β2-agonists is associated with poor asthma outcomes: results from the Latin American cohort of the SABINA III study. *J Asthma* 2022; in press [https://doi.org/10.1080/02770903.2022.2082305].

14 Nwaru BI, Ekström M, Hasvold P, et al. Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. *Eur Respir J* 2020; 55: 1901872.

15 Shen SY, Chen CW, Liu TC, et al. SABA prescriptions and asthma management practices in patients treated by specialists in Taiwan: Results from the SABINA III study. *J Formos Med Assoc* 2022; in press [https://doi.org/10.1016/j.jfma.2022.05.014].

16 Di Marco F, D’Amato M, Lombardo FP, et al. The burden of short-acting β2-agonist use in asthma: is there an Italian case? An update from SABINA program. *Adv Ther* 2021; 38: 3816–3830.

17 Blakeston S, Harper G, Zabala Mancebo J. Identifying the drivers of patients’ reliance on short-acting β2-agonists in asthma. *J Asthma* 2021; 58: 1094–1101.

18 Zhao H, Li R, Lv Y, et al. Albuterol inhalation increases FeNO level in steroid-naive asthmatics but not COPD patients with reversibility. *Clin Respir J* 2017; 11: 328–336.

19 Gomem S, Cumella A, Richardson M. Asthma admission rates and patterns of salbutamol and inhaled corticosteroid prescribing in England from 2013 to 2017. *Thorax* 2019; 74: 705–706.

20 Mckibben S, Bush A, Thomas M, et al. "Tossing a coin": defining the excessive use of short-acting β2-agonists in asthma – the views of general practitioners and asthma experts in primary and secondary care. *NPJ Prim Care Respir Med* 2018; 28: 26.

21 Janson C, Henderson R, Löfdahl M, et al. Carbon footprint impact of the choice of inhalers for asthma and COPD. *Thorax* 2020; 75: 82–84.

22 Haahtela T, Alanko K, Muittari A, et al. The superiority of combination beclomethasone and salbutamol over standard dosing of salbutamol in the treatment of chronic asthma. *Ann Allergy* 1989; 62: 63–66.

23 Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2022. Available from: https://ginasthma.org/.

24 Crossingham I, Turner S, Ramakrishnan S, et al. Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma. *Cochrane Database Syst Rev* 2021; 5: CD013518.

25 Jenkins CR, Bateman ED, Sears MR, et al. What have we learnt about asthma control from trials of budesonide/formoterol as maintenance and reliever? *Respirology* 2020; 25: 804–815.

26 Papi A, Corradi M, Pigeon-Francisco C, et al. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. *Lancet Respir Med* 2013; 1: 23–31.

27 Wilkinson A, Menzies-Gow A, Sawyer M, et al. S26 An assessment of short-acting β2-agonist (SABA) use and subsequent greenhouse gas (GHG) emissions in five European countries and the consequence of their potential overuse for asthma in the UK. *Thorax* 2021; 76: Suppl. 1, A19–A19.

28 WHO. Protecting health from climate change: Global research priorities. https://www.who.int/publications/i/item/protecting-health-from-climate-change-global-research-priorities Date last accessed: February 22, 2022. Date last accessed: 22 February 2022.

29 Chapman KR, Hinds D, Piazza P, et al. Physician perspectives on the burden and management of asthma in six countries: the Global Asthma Physician Survey (GAPS). *BMC Pulm Med* 2017; 17: 153.

30 Crowther L, Pearson M, Cummings H, et al. Towards codesign in respiratory care: development of an implementation-ready intervention to improve guideline-adherent adult asthma care across primary and secondary care settings (the SENTINEL Project). *BMJ Open Respir Res* 2022; 9: e001155.

31 Crooks M, Crowther L, Cummings H, et al. Impact of maintenance and reliever therapy (MART)-focused asthma guideline on SABA prescriptions. *Eur Respir J* 2021; 58: Suppl. 65, OA80.

https://doi.org/10.1183/23120541.00353-2022